AIKI vs. XELB, FNJN, NOTV, ONMD, BIAF, DKDCA, ISPC, FOXO, REFR, and ACTG
Should you be buying AIkido Pharma stock or one of its competitors? The main competitors of AIkido Pharma include Xcel Brands (XELB), Finjan (FNJN), Inotiv (NOTV), OneMedNet (ONMD), bioAffinity Technologies (BIAF), Data Knights Acquisition (DKDCA), iSpecimen (ISPC), FOXO Technologies (FOXO), Research Frontiers (REFR), and Acacia Research (ACTG).
Xcel Brands (NASDAQ:XELB) and AIkido Pharma (NASDAQ:AIKI) are both small-cap retail/wholesale companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends, community ranking, risk and media sentiment.
Xcel Brands received 133 more outperform votes than AIkido Pharma when rated by MarketBeat users. However, 63.92% of users gave AIkido Pharma an outperform vote while only 49.58% of users gave Xcel Brands an outperform vote.
AIkido Pharma has lower revenue, but higher earnings than Xcel Brands. Xcel Brands is trading at a lower price-to-earnings ratio than AIkido Pharma, indicating that it is currently the more affordable of the two stocks.
AIkido Pharma has a net margin of 0.00% compared to AIkido Pharma's net margin of -156.27%. Xcel Brands' return on equity of -18.21% beat AIkido Pharma's return on equity.
In the previous week, Xcel Brands had 2 more articles in the media than AIkido Pharma. MarketBeat recorded 2 mentions for Xcel Brands and 0 mentions for AIkido Pharma. Xcel Brands' average media sentiment score of 0.00 beat AIkido Pharma's score of -0.47 indicating that AIkido Pharma is being referred to more favorably in the news media.
Xcel Brands has a beta of 1.47, suggesting that its share price is 47% more volatile than the S&P 500. Comparatively, AIkido Pharma has a beta of 0.93, suggesting that its share price is 7% less volatile than the S&P 500.
18.6% of Xcel Brands shares are owned by institutional investors. Comparatively, 10.9% of AIkido Pharma shares are owned by institutional investors. 52.4% of Xcel Brands shares are owned by insiders. Comparatively, 8.6% of AIkido Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
Xcel Brands beats AIkido Pharma on 8 of the 15 factors compared between the two stocks.
Get AIkido Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for AIKI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AIKI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
AIkido Pharma Competitors List
Related Companies and Tools
